These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6124557)

  • 1. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol.
    O'Connor DT; Barg AP; Duchin KL
    J Clin Pharmacol; 1982 Apr; 22(4):187-95. PubMed ID: 6124557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.
    Dupont AG; Vanderniepen P; Bossuyt AM; Jonckheer MH; Six RO
    Br J Clin Pharmacol; 1985 Aug; 20(2):93-9. PubMed ID: 2864051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term renal hemodynamic effects of nadolol in patients with essential hypertension.
    Frohlich ED; Messerli FH; Deslinski GR; Kobrin I
    Am Heart J; 1984 Oct; 108(4 Pt 2):1141-3. PubMed ID: 6148875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of tertatolol and nadolol on systemic and renal hemodynamics in patients with essential hypertension.
    Degaute JP; Naeije R; Abramowicz M; Leeman M; Schoutens A; Prost JF
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):263S-268S. PubMed ID: 3415803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blockers and the kidney.
    Epstein M; Oster JR
    Miner Electrolyte Metab; 1982 Nov; 8(5):237-54. PubMed ID: 6132329
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison between short-term renal haemodynamic effects of propranolol and nadolol in essential hypertension: a cross-over study.
    Danesh BJ; Brunton J; Sumner DJ
    Clin Sci (Lond); 1984 Aug; 67(2):243-8. PubMed ID: 6146425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nadolol in treatment of hypertension.
    Volicer L; Liang CS; Gavras H; Tifft CP; Kershaw GR; Gavras I; Griffith DL; Vukovitch R; Brunner HR
    J Clin Pharmacol; 1979; 19(2-3):137-47. PubMed ID: 33998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients.
    O'Callaghan WG; Laher MS; McGarry K; O'Brien E; O'Malley K
    Br J Clin Pharmacol; 1983 Oct; 16(4):417-21. PubMed ID: 6138058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the antihypertensive and renal effects of tertatolol and nadolol in hypertensive patients with mild renal impairment.
    Fallo F; Gregianin M; Bui F; Macrì C; Folino P; Mantero F
    Eur J Clin Pharmacol; 1991; 40(3):309-11. PubMed ID: 1676368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension.
    Gatta A; Sacerdoti D; Merkel C; Milani L; Battaglia G; Zuin R
    Am Heart J; 1984 Oct; 108(4 Pt 2):1167-72. PubMed ID: 6148880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of carvedilol on renal function.
    Dupont AG
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S96-100. PubMed ID: 1974513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension.
    Frithz G
    Curr Med Res Opin; 1978; 5(5):383-7. PubMed ID: 26519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal perfusion is preserved during cardioselective beta-blockade with metoprolol in hypertension.
    Sugino G; Barg AP; O'Connor DT
    Am J Kidney Dis; 1984 Mar; 3(5):357-61. PubMed ID: 6702821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nadolol on systemic and renal hemodynamics in patients with renoparenchymal hypertension and various degrees of renal function.
    Valvo E; Gammaro L; Bedogna V; Cavaggioni M; Tonon M; Lupo A; Loschiavo C; Tessitore N; Oldrizzi L; Rugiu G
    Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):202-6. PubMed ID: 3710633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nadolol (Corgard) - a new beta-blocker.
    Med Lett Drugs Ther; 1980 Apr; 22(8):33-4. PubMed ID: 6102734
    [No Abstract]   [Full Text] [Related]  

  • 16. Beta-adrenergic blockade alone does not decrease renal perfusion in black hypertensives.
    Brater DC; Anderson S; Kaplan NM; Ram CV
    J Hypertens; 1984 Feb; 2(1):43-8. PubMed ID: 6152277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nadolol, a long-term acting beta blocking agent, in the treatment of essential arterial hypertension].
    Semplicini A; Pessina AC; Rossi GP; Tagliafierro R; Lusiani L; Castellani V; Bedogni F; Mazzucato A; Ronsisvalle G
    Cardiologia; 1982 Sep; 27(9):853-64. PubMed ID: 6765278
    [No Abstract]   [Full Text] [Related]  

  • 18. The kidney and strategies for the treatment of hypertension.
    Hollenberg NK
    Am J Med; 1984 Oct; 77(4A):60-3. PubMed ID: 6207726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function in patients with essential hypertension receiving nadolol.
    Waal-Manning HJ; Hobson CH
    Br Med J; 1980 Aug; 281(6237):423-4. PubMed ID: 6107151
    [No Abstract]   [Full Text] [Related]  

  • 20. Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol.
    Mancia G; Ferrari A; Pomidossi G; Parati G; Bertinieri G; Grassi G; Gregorini L; di Rienzo M; Zanchetti A
    Am Heart J; 1984 Oct; 108(4 Pt 2):1078-83. PubMed ID: 6148866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.